AngioDynamics reported Q3 revenue of $79.4 million, up 8.8% year-over-year on a pro forma basis and higher than the consensus ...

Q2 2026 Earnings Call Transcript January 6, 2026 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is ...

AngioDynamics, Inc. ANGO reported breakeven adjusted earnings per share for second-quarter fiscal 2026, marking an ...

AngioDynamics raised its full-year sales outlook after logging a higher top line in its fiscal second quarter, as the company scooped up market share from competitors. The medical-technology company ...

The news release detailing AngioDynamics' fiscal 2026 first quarter results crossed the wire earlier this morning and is ...

Q2 FY2026 earnings call recap: revenue up 8.8%, Auryon & NanoKnife growth, raised guidance, margin outlook and risks—read now.

Shares of AngioDynamics were trading at $12.68 as of January 02. Over the last 52-week period, shares are up 34.89%. Given that these returns are generally positive, long-term shareholders should be ...

AngioDynamics stock is undervalued, with Med Tech growth in thrombus management and atherectomy. Learn more about the company ...

Canaccord Genuity analyst William Plovanic maintained a Buy rating and raised the price target from $17 to $18 on Oct. 3, ...

AngioDynamics’ Med Tech segment delivered its fifth consecutive quarter of double-digit growth, increasing 13.0% to $35.7 million. This growth was led by the Auryon peripheral atherectomy platform, ...

AngioDynamics’ DIRECT clinical study features a comprehensive data collection strategy that will provide meaningful clinical information to healthcare professionals, support a regulatory indication ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, ...